e-learning
resources
ERJ
2007
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Antimicrobial peptides in the real world: implications for cystic fibrosis
Hiemstra P. S.
Source:
Eur Respir J 2007; 29: 617-618
Journal Issue:
April
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Hiemstra P. S.. Antimicrobial peptides in the real world: implications for cystic fibrosis. Eur Respir J 2007; 29: 617-618
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
Managing antimicrobial resistance in cystic fibrosis
Source: International Congress 2014 – ERS/Lancet and Lancet Respiratory Medicine joint session: complicating infections in respiratory disease and critical care
Year: 2014
The role of antimicrobial peptides in cystic fibrosis in childhood.
Source: International Congress 2019 – Infection and inflammation in cystic fibrosis
Year: 2019
Biofilms and how to combat them: examples from cystic fibrosis
Source: Virtual Congress 2020 – Antibiotic resistance: the way forward
Year: 2020
Emerging pathogens in cystic fibrosis
Source: International Congress 2019 – State of the art session: Paediatric respiratory diseases
Year: 2019
Cystic fibrosis: prospects for therapy of some class 1 mutations
Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver?
Year: 2007
Emerging pathogens in cystic fibrosis
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66
Year: 2006
Cystic fibrosis microbiology, emerging pathogens and more treatment options
Source: International Congress 2018 – PG10 Cystic fibrosis: Basic defects and clinical problems in children
Year: 2018
Novel therapeutics for cystic fibrosis
Source: ERS Webinar 2020: Novel therapeutics for cystic fibrosis
Year: 2020
Genomically-guided therapies: a new era for cystic fibrosis
Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases
Year: 2020
Newborn screening for cystic fibrosis: opportunities and remaining challenges
Source: Eur Respir Monogr 2014; 64: 65-76
Year: 2014
Disease modifying genes: The cystic fibrosis lesson
Source: Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases
Year: 2004
Update on new treatments for cystic fibrosis
Source: Virtual Congress 2020 – Updates in cystic fibrosis
Year: 2020
What’s new in cystic fibrosis?
Source: International Congress 2018 – Paediatric Year in Review
Year: 2018
Molecular detection of complex microbial communities in sputa of patients with cystic fibrosis and non cystic fibrosis bronchiectasis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010
Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysis
Source: Eur Respir J, 50 (2) 1700763; 10.1183/13993003.00763-2017
Year: 2017
Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise?
Source: Eur Respir J 2007; 29: 229-230
Year: 2007
Current concepts: host–pathogen interactions in cystic fibrosis airways disease
Source: Eur Respir Rev 2014; 23: 320-332
Year: 2014
The characteristics of the minimum inhibitory concentration of antibiotics on pulmonary infections in patients with cystic fibrosis
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
Host specificity of
pseudomonas
aeruginosa
isolates from patients with cystic fibrosis and patients from different clinical backgrounds
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014
A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators
Source: Eur Respir Rev, 27 (148) 170124; 10.1183/16000617.0124-2017
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept